A Phase I Trial of BKM120 in Combination With Weekly Nabpaclitaxel (Abraxane) in Patients With Advanced Solid Tumors Followed by a Dose Expansion Phase in Patients With Recurrent Endometrial or Recurrent Ovarian Cancer

Trial Profile

A Phase I Trial of BKM120 in Combination With Weekly Nabpaclitaxel (Abraxane) in Patients With Advanced Solid Tumors Followed by a Dose Expansion Phase in Patients With Recurrent Endometrial or Recurrent Ovarian Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2015

At a glance

  • Drugs Buparlisib (Primary) ; Paclitaxel (Primary)
  • Indications Endometrial cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Mar 2015 Last checked against ClinicalTrials.gov record.
    • 19 Mar 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
    • 29 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top